CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Walls, Gerard M., Oughton, Jamie B., Chalmers, Anthony J., Brown, Sarah, Collinson, Fiona, Forster, Martin D., Franks, Kevin N., Gilbert, Alexandra, Hanna, Gerard G., Hannaway, Nicola, Harrow, Stephen, Haswell, Tom, Hiley, Crispin T., Hinsley, Samantha, Krebs, Matthew, Murden, Geraldine, Phillip, Rachel, Ryan, Anderson J., Salem, Ahmed, Sebag-Montefoire, David, Shaw, Paul ORCID: https://orcid.org/0000-0002-7467-0619, Twelves, Chris J., Walker, Katrina, Young, Robin J., Faivre-Finn, Corinne and Greystoke, Alastair 2020. CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clinical and Translational Radiation Oncology 25 , pp. 61-66. 10.1016/j.ctro.2020.09.006

Full text not available from this repository.

Abstract

Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for ‘gold standard’ treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences
Publisher:	Elsevier
ISSN:	2405-6308
Date of First Compliant Deposit:	26 October 2020
Date of Acceptance:	15 September 2020
Last Modified:	09 Nov 2022 09:29
URI:	https://orca.cardiff.ac.uk/id/eprint/135916

Citation Data

Cited 10 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item